This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Abstract

Background

Increased cellular iron exposure is associated with colorectal cancer (CRC) risk.
Hepcidin, a liver peptide hormone, acts as the primary regulator of systemic iron
status by blocking iron release from enterocytes into plasma. Concentrations are decreased
during low iron status and increased during inflammation. The role of hepcidin and
the factors influencing its regulation in CRC remains largely unknown. This study
explored systemic and tumor level iron regulation in men with CRC.

Conclusions

While CRC subjects had serum hepcidin concentrations in the normal range, it was higher
given their degree of iron restriction. Inappropriately elevated serum hepcidin may
reduce duodenal iron absorption and further increase colonic adenocarcinoma iron exposure.
Future clinical studies need to assess the appropriateness of dietary iron intake
or iron supplementation in patients with CRC.

Keywords:

Iron metabolism; Hepcidin; Inflammation; Anemia; Colorectal cancer

Background

Excessive body iron levels are associated with increased risk for colorectal cancer
(CRC)
[1-6]. This is due to the high oxidative potential of iron which can result in the formation
of reactive oxygen species and mutate the DNA of key genes involved in cell proliferation
[2]. Additionally, since iron is required for cell proliferation, increased iron levels
could contribute to tumor promotion
[1].

Iron levels and its tissue distribution in the body are regulated by hepcidin, a hepatic-derived
systemic iron regulatory hormone
[7-9]. Hepcidin is increased by inflammation and decreased by iron insufficiency and erythropoiesis
[10-12]. Mechanistically, hepcidin controls iron release into plasma by degrading the iron
exporter ferroportin (FPN) in cells that handle iron, including intestinal enterocytes,
hepatocytes, and macrophages
[13]. Thus, when concentrations of hepcidin are elevated, FPN expression is low, resulting
in reduced dietary iron absorption and impaired mobilization from stores.

Few studies have assessed the role of hepcidin and FPN in cancer
[14,15]. Serum hepcidin levels were found to be elevated in some hematologic or nonhematologic
cancers, likely because of the presence of inflammation, but the pathophysiological
relevance of these findings is unknown
[16,17]. For FPN, it was reported that patients with breast cancer had decreased tumor expression
of FPN protein compared to non-involved tissue, and that tumor FPN mRNA levels were
negatively correlated with advanced staging
[14]. This suggested that iron retention by breast cancer cells may affect cancer progression.

Hepcidin may be elevated in persons with CRC due to cancer-induced inflammation
[18,19]. However, because CRC patients frequently have anemia or low iron status, hepcidin
levels may also be decreased
[20,21]. Evaluation of the involvement of hepcidin in regulating systemic and tumor level
iron metabolism in CRC is limited to one study
[15]. Ward et al. reported that systemic hepcidin is elevated with advanced cancer staging
[15]. Additionally, they demonstrated that mRNA expression of hepcidin is detected within
a subset (34%) of colonic tumors compared to healthy non-involved mucosa. In a complementary
study by Brookes et al., increases in iron acquisition proteins (Divalent metal transporter-1,
DMT-1; Transferrin receptor-1, TfR1) and decreases in proteins related to cellular
iron efflux (FPN; Hephaestin, Heph) were noted in colonic tumors when compared to
non-involved mucosa
[1]. The authors suggested that these alterations in iron transport may explain the iron
sequestration commonly observed in colonic tumors
[1]. What remains unknown is hepcidin’s role in regulating colonocyte iron transport
and whether it contributes to tumor iron accumulation in persons with CRC.

The purpose of this study was to examine simultaneously systemic and tumor iron status
and their regulation in men with CRC compared to controls. This was assessed by measuring:
(i) hepcidin, iron status and markers of inflammation in serum and (ii) hepcidin,
expression of iron transporters (DMT-1, FPN), inflammation and iron accumulation in
colonic mucosa. We hypothesized that CRC would be associated with higher levels of
hepcidin in serum and tumor compared to controls and that hepcidin levels would be
correlated with markers of inflammation and mucosal iron accumulation.

Methods

Ethics

All subjects signed an informed consent and the study procedures were approved by
the University of Illinois at Chicago Institutional Review Board.

Study population and characteristics

Study subjects were recruited from patients scheduled for colonoscopies due to abdominal
pain, bloating, change in bowel movements or for CRC screening at the University of
Illinois at Chicago and John H. Stroger Jr. Cook County Hospital between May 2011
and June 2012. "Cases" were classified as newly diagnosed CRC with adenocarcinoma
based on pathology reports for their tumor biopsies; "controls" were selected from
the subjects with healthy colonic mucosa (absence of adenomatous polyps or GI abnormalities).
Cases and controls (n = 20/group) were matched to have a similar difference within
each pair for age (within 5 years), body mass index (BMI) (within 4 units) and waist
circumference (within 5 cm). Due to gender-specific variation in reference ranges
for iron parameters, participation was restricted to males. Additional exclusions
included medical conditions that could affect iron status such as gastrointestinal
bleeding, hemochromatosis, history of inflammatory bowel disease or infection.

Following informed consent, questionnaires for basic demographic information, health
history, medication and supplement use and alcohol consumption were administered by
a research team member. The Block Brief 2000 food frequency questionnaire (FFQ) was
used to assess usual dietary intake over the previous 12 months
[22]. Height was measured with a stadiometer to nearest 0.1 cm and weight using a balance
beam scale to nearest 0.1 kilograms with subjects wearing a hospital gown. Waist circumference
was measured with a flexible tape (AccuFitness, Greenwood Village, CO) at the midpoint
between the ribs and iliac crest, to the nearest 0.1 cm. Body mass index was calculated
as weight in kilograms divided by height in meters squared. CRC staging (0-IV) based
on tumor size, lymph nodes affected and metastasis (TNM) was classified using the
American Joint Committee on Cancer (AJCC) criteria
[23].

Laboratory assays

All blood samples were collected after a minimum 12 hour fast following the endoscopy
or prior to surgical intervention. A separate analysis did not reveal any differences
in serum parameters by blood collection type. Colonic adenocarcinoma tissue was obtained
from cases at the time of surgical resection. Healthy colonic mucosa from the descending
colon in the controls was obtained using standard sized biopsy forceps during colonoscopy.

Tissue specimen

A portion of colonic tissue was placed in formalin and paraffin-embedded for histological
analysis. The remaining portion of the colonic tissue was placed in RNAlater (Ambion,
Austin, TX) and stored at -80°C for gene expression (mRNA) analysis.

Real time polymerase chain reaction (RT-PCR)

Total RNA was extracted from colonic mucosa sections using the Maxwell 16 System (Promega,
Fitchburg, WI). The complementary DNA was synthesized from the RNA using iScript™
cDNA Synthesis Kit (BioRad, Hercules, CA). Gene expression (mRNA) of divalent metal
transporter-1 (DMT-1), ferroportin (FPN), hepcidin and IL-6 were measured quantitatively
by RT-PCR (For primers used see Additional file
1) using SsoAdvanced SYBR Green Supermix (BioRad). Amplifications were performed at
57°C for 40 cycles using the C1000 Touch (BioRad) and data analyzed using the CFX
Manager software (BioRad). Results were normalized to reference genes Glyceraldehyde
3-phosphate dehydrogenase (GADPH) and β-actin to obtain ΔCt values (ΔCt = Ct[reference]
- Ct[target]). As both GADPH and β-actin showed equivalent results, we used the average
of the two values for the final representation. Fold change in mRNA expression in
cases compared to controls was calculated using 2ΔΔCt, where ΔΔCt = average ΔCt for cases - average ΔCt for controls. Statistical comparison
was performed using raw ΔCt values (Additional file
2).

Iron staining

Tissue iron accumulation was measured qualitatively by Perls’ Prussian blue staining.
The tissue section was treated with dilute hydrochloric acid to release ferric ions
from binding proteins. These ions then reacted with potassium ferrocyanide to produce
an insoluble blue compound (the Prussian blue reaction). The grading of iron staining
was performed by a pathologist blinded to the experimental group and reported dichotomously
as presence or absence of iron accumulation (+/-).

Statistical analysis

Prior to analysis, all variables were assessed for normality and presence of outliers.
Descriptive statistics included mean, standard deviation (SD), median and interquartile
range (IQR) for continuous variables and frequencies for categorical variables. Difference
between cases and controls was assessed by student’s paired t-test or non-parametric Wilcoxon signed-rank test for continuous variables and McNemar’s
test for categorical variables. Non-parametric Spearman’s Rank correlation coefficient
was used to explore bivariate relationships. Multivariable linear regression was performed
to adjust for confounders. All analyses were performed using SAS version 9.3 (Cary,
North Carolina). P-values were two-sided and the statistical significance level was
defined as p < 0.05.

Results

Subject characteristics are presented in Table
1. By design cases and controls were similar in age, BMI and waist circumference. Race/ethnicity,
dietary iron intake (heme and non-heme food and supplemental sources), medication
use and alcohol consumption were also similar between cases and controls.

Systemic iron regulation and inflammation

Systemic iron status and inflammatory parameters are presented in Table
2. Cases had significantly lower Hb and higher sTfR compared to controls (p < 0.05),
indicative of iron-restricted erythropoiesis. Serum hepcidin was mildly decreased
in cases, likely as a response to the increased erythroid iron demand (as reflected
by the elevated sTfR). However, considering that hepcidin concentrations were still
in the normal range for cases, hepcidin may be elevated given their degree of iron
restriction. Hepcidin is known to be low or undetectable in individuals with insufficient
iron status
[8]. Cases also had significantly elevated CRP (p < 0.05) and a trend toward increased
IL-6 concentrations compared to controls, indicating the presence of mild inflammation
in these patients. This may stimulate hepcidin production and counterbalance the suppressive
effect of iron-restricted erythropoiesis on hepcidin.

Table 2.Iron status and markers of inflammation in serum between cases and controls

Associations between serum hepcidin and iron status and inflammatory parameters were
explored with Spearman correlation coefficients. In controls, serum hepcidin was correlated
with Hb (r = 0.54; p = 0.01) as expected, and no associations were found with sTfR
or inflammatory markers (CRP, IL-6, TNF-α), which were in the normal range. In cases,
serum hepcidin was not correlated with any of the parameters (Hb, sTfR or the inflammatory
markers). Additionally, cancer staging did not change serum hepcidin concentrations
(Stage IV: median 64.4 (IQR 249.1) versus Stage I: 72.8 (IQR 28.7) ng/mL p = 1.0).
Since our lab previously demonstrated that obesity-induced inflammation is associated
with elevated serum hepcidin levels, we stratified cases and controls by obesity status
(obese ≥ 102 cm, lean < 102 cm)
[26,27]. Within cases, circulating markers of inflammation and serum hepcidin did not differ
by obesity status (data not shown). Obese controls were more inflamed (CRP, IL-6)
compared to lean; however, serum hepcidin concentrations were similar between the
groups.

Iron transporters in colonic mucosa

Gene expression (mRNA) of hepcidin, iron transporters (DMT-1 and FPN) and the pro-inflammatory
protein IL-6 in colonic mucosa are presented in Table
3. Expression of DMT-1 and FPN were similar between cases and controls. Although cases
had a 2.9-fold lower expression of hepcidin compared to controls (p < 0.05), overall
both groups expressed very low hepcidin mRNA in the colonic mucosa (close to the limit
of detection by qPCR). Cases had a 9.4-fold higher expression of IL-6 compared to
controls (p < 0.05), confirming the inflammatory nature of the tumor. Correlation
analyses did not reveal significant associations between expression of the serum and
colonic markers of iron regulation, iron transport or inflammation in cases or controls
(data not shown).

Iron accumulation in colonic mucosa

To determine if CRC was associated with greater tissue iron accumulation, adenocarcinoma
from cases and healthy colonic mucosa from controls was examined using Perls’ Prussian
blue stain. Iron accumulation was present in more cases than controls (n = 6/20; 30%;
n = 1/20; 5%, χ2 = 5.00; p < 0.05). Illustrative Perls’ stains are shown in Figure
1 (cases A-B, controls C-D). When cases were dichotomized by presence/absence of iron
accumulation (+/-), cases with iron accumulation had higher serum hepcidin compared
to the cases without iron accumulation (p < 0.05) (Table
4). However, after adjusting for Hb, differences in serum hepcidin between these subgroups
became non-significant. This suggests that systemic iron sufficiency may have contributed
to the higher serum hepcidin observed in the iron accumulation (+) group given that
hepcidin is increased when iron stores are adequate. In support, there was a trend
for lower sTfR in the iron (+) group, demonstrating iron bioavailability. Differences
in systemic inflammatory markers (CRP, IL-6 or TNF-α) between cases with different
iron accumulation (+/-) were non-significant. Additionally, no differences were observed
for tissue level (mRNA expression for DMT-1, FPN, hepcidin, IL-6) parameters or with
cancer staging (data not shown).

Table 4.Iron status and markers of inflammation in serum between cases with colonic iron presence
(+) and without iron presence (-)

Discussion

Individuals with CRC frequently have anemia or low iron status which may, at least
in part, be due to an inflammatory response termed the anemia of chronic disease (ACD)
[18,20,21,28,29]. The ACD is thought to manifest through increased hepatic production of the iron
regulatory protein hepcidin, which can down-regulate the iron exporter FPN
[10,13,30]. Reduction of FPN limits iron flow into circulation from both the diet and storage
sites and promotes tissue iron sequestration. Beyond impaired iron status and red
blood cell production, the ACD may be relevant for persons with CRC given that hepcidin-induced
reductions in dietary iron absorption in the proximal gut may increase colonic iron
exposure. Colonic tumors may benefit from this alteration since iron is a substrate
for cell proliferation, cancer progression and metastasis
[1,2,5,6]. The primary aims of this case–control study were to simultaneously examine systemic
and tumor level iron status and regulation in men with CRC compared to controls and
determine if systemic or tumor level hepcidin expression was associated with tumor
iron accumulation.

We found cases had significantly more iron-restricted erythropoiesis based on Hb and
sTfR compared to controls. We could not differentiate whether this mild anemia was
due to inflammation or also to frank iron deficiency. Often, gastrointestinal bleeding
can contribute to iron deficiency in CRC; however, we excluded persons with known
gastrointestinal bleeding, suggesting other factors contributed to the iron restriction
observed in cases
[29,31]. Typically when iron deficiency is present, serum hepcidin concentrations are undetectable
[8]. Indeed, cases had lower serum hepcidin compared to controls; however, this difference
was not significant and was within the normal range. This suggests hepcidin levels
were inappropriately elevated given the patients’ iron-restricted erythropoiesis.
Hepcidin expression is simultaneously regulated by inflammation, iron stores and erythropoiesis
[7,10]. Further, hepcidin levels are ultimately determined by the relative strength of these
opposing stimuli
[12,32]. In contrast to controls where serum hepcidin was correlated with Hb, serum hepcidin
within cases was not significantly correlated with Hb suggesting that multiple signals
may be influencing its production. Significantly greater systemic and colonic mucosal
inflammation was observed in cases compared to controls which may have provided the
necessary stimuli to promote increased hepatic hepcidin production, despite elevated
sTfR and low iron status. This phenotype, in which serum hepcidin is simultaneously
regulated by low iron status and inflammation, has been previously reported in morbid
obesity
[26,33,34]. Similar to our cases, obese participants in these studies presented with low iron
status, elevated systemic inflammation and serum hepcidin concentrations within the
normal range
[26]. Like obesity, the iron profile observed in our cases is consistent with a mixed
anemia for which hallmarks of the ACD and iron deficiency coexist
[9]. This phenotype allows for the mobilization of iron from body stores but impairs
iron repletion as a result of reduced dietary iron absorption
[35]. Therefore, over time, inflammation-induced chronically elevated hepcidin would precipitate
cellular iron depletion as body iron losses exceed dietary absorption effort
[27,36]. Importantly, this type of mixed anemia has the potential to increase gastrointestinal
iron exposure in persons with CRC.

We assessed colonic mucosal iron transport and regulation and found no statistical
difference in expression of DMT-1 or FPN between cases and controls. Directionally
our DMT-1 and FPN expression were similar to those of Brookes et al.
[1]. They reported increased colonocyte expression of iron influx (DMT-1) and decreased
iron efflux (FPN) proteins in CRC compared to controls. This suggests that CRC tissue
is associated with greater colonic adenocarcinoma iron uptake and sequestration compared
to healthy mucosa. We observed very low hepcidin expression in the colonic tumors
and healthy mucosa. This is not unexpected given that hepcidin is primarily produced
in hepatocytes. In our previous analysis, abdominal subcutaneous and visceral adipose
tissue also expressed very low mRNA expression compared to the liver
[26]. Very little is known regarding the role of extra-hepatic hepcidin in systemic and
tissue-level iron regulation. Our findings indicate that colonic hepcidin has a minimal
role in tumor iron regulation. Ward et al. reported elevated tumor hepcidin expression within 34% of cases compared to non-involved
healthy mucosa; however, other factors that regulate hepcidin expression including
inflammation, iron status and dietary iron intake were not examined, limiting interpretations
of their findings
[15]. Given that few studies have examined the role of extra-hepatic hepcidin in regulating
systemic or tissue-level iron metabolism, further investigations are warranted to
understand mechanisms related to iron metabolism in colonic tumors
[15,37-39].

We observed significantly more cases (30%) had detectable iron accumulation compared
to controls (5%). Perls’ staining has relatively low sensitivity. We speculate iron
accumulation would have been much more prevalent in cases had we used a more sensitive
assessment method. Brookes et al. used DAB-enhanced Perls’ methodology and detected visible iron accumulation in all
(n = 20) of the CRC cases but not controls
[1]. To further characterize the cases with iron accumulation, we examined systemic hepcidin
and iron status parameters. The iron (+) group had elevated serum hepcidin compared
to cases without iron accumulation. However, the iron (+) group was also more iron
sufficient and had higher Hb. Given the small sample of cases with iron accumulation,
it is hard to make any definitive conclusions. However, our data coupled with the
report by Brookes et al. suggests that a subset of persons with CRC have increased expression of systemic
hepcidin, which may precipitate greater intestinal iron exposure, and promote tumor
iron retention
[1]. In a murine model of CRC, animals had increased tumor growth when fed a high iron
diet compared to a low iron diet
[5]. Also, in persons with ulcerative colitis (UC), who have co-existing systemic and
colonic inflammation and hepcidin-mediated dietary iron malabsorption, luminal iron
exposure is associated with greater colonic inflammation and mucosal proliferation
[40-42]. Therefore, studies examining the effect of dietary iron restriction in persons with
CRC should be explored.

The link with hepcidin and excess tumor iron accumulation provides further evidence
for its role in cancer. Only one other study has comprehensively explored the hepcidin-FPN
axis and its relationship in cancer progression. Pinnix et al. using human breast cancer tissue found that low FPN and high hepcidin expression
may enable rapid cell proliferation
[14]. Unfortunately, the authors did not measure systemic hepcidin concentrations and
future exploration should focus on its role in tumor iron retention in other epithelial
cancers.

Our study had strengths and limitations. A significant strength was that we simultaneously
measured hepcidin systemically and in colonic mucosa while accounting for several
factors that can contribute to hepcidin regulation, including iron status, inflammation
and dietary iron intake. Additionally, we included a metabolically healthy control
group. However, this study had limitations, including a relatively small sample size.
Therefore, when we stratified by presence of iron accumulation in the CRC cases, this
may have reduced the statistical power to detect differences. Tissue analysis with
adenocarcinoma in cases to healthy mucosa in a control group was not a direct comparison.
Future studies should also include non-involved mucosa in cases to accurately describe
our analysis among all groups. Due to limited tissue allocated for this study, we
were unable to accurately measure protein expression of the colonic iron exporter
via FPN. Ferroportin is post-translationally modified by hepcidin, which may have
precluded us from observing a significant correlation between colonic FPN and hepcidin.
Although we suggest dietary iron absorption may be impaired in persons with CRC, we
did not examine dietary iron absorption in this study. Finally, our design included
only males, thus generalizability to females may be limited.

Conclusion

In summary, our study demonstrates for the first time that CRC in some men is associated
with a mixed anemia pathology characterized by iron restricted erythropoiesis. We
believe the simultaneous presence of inflammation (increases hepcidin) and iron insufficiency
(suppresses hepcidin) in a subset of our men with CRC resulted in hepcidin concentrations
inappropriately elevated given their depleted iron status. Further, these findings
suggest that systemic hepcidin in some CRC cases may 1) decrease duodenal iron absorption
resulting in low iron status and 2) contribute to excess colonic iron exposure and
disease promotion. Given the high incidence of CRC and the accompanying low iron status,
these findings could have significant clinical implications
[21,43]. Future investigations into the risks and benefits of dietary iron intake and oral
iron supplementation in persons with CRC are warranted.

Competing interests

All of the authors declare they have no competing interests.

Authors’ contributions

CKP and CB designed the research. CKP, JC and XL acquired the data. CKP, SF, RJC,
RL and DN analyzed the data. CKP, SF, EN, GF, LTH, and CB interpreted the data. CKP
wrote the manuscript draft. CKP, EN, GF, LTH, and CB critically revised the manuscript.
All authors read and approved the final manuscript.

Acknowledgments

The efforts of this study were supported by 5R25CA057699 from the National Cancer
Institute. EN is affiliated with Intrinsic LifeSciences, the company that assessed
the serum samples for hepcidin.